My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
CARRION-MADRONAL, IM; SANCHEZ-DEL MORAL, R and VILLALBA-MORENO, AM. Dalbavancin as prolonged-salvage treatment in prosthetic joint infection. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.4, pp.423-424. Epub Sep 19, 2022. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x20210004000016.
Dalbavancin is an antibacterial agent that belongs to the group of semisynthetic lipoglicopeptides of long half-life, with great activity in grampositive microorganisms and with an acceptable adverse effects profile. To date, it has been authorized for the treatment of skin and soft tissue infections in adults, with no indication ofbone and joint infections.
Most cases of joint prosthetic infection described in the literature with dalbavancin in prolonged treatment have been for a period not exceeding 4 weeks. A series of cases of prosthetic joint infection treated for a long time and as salvage with dalbavancin are described
Keywords : Dalbavancin; methicillin-resistant Staphylococcus; prolonged treatment; prosthetic joint infection.